Climb Bio guides to funding into late 2028 as ITP data near

Climb Bio, the US antibody company, has told investors it expects its current cash to last into the second half of 2028. The projection appears in a corporate presentation dated November 2026. For a clinical-stage business with no products on the market, that timeframe sets the window in which it must deliver data, and perhaps raise capital or strike partnerships, if it is to keep its programmes moving.

The presentation also says the company met its data guidance for 2026. The next disclosure on the calendar is an update in immune thrombocytopenia (ITP), planned for the American Society of Hematology meeting in December. Climb Bio says more data are due in 2027. The company's own summary, which is all we have seen, gives no detail on the results or on what the 2027 readouts will cover.

The pipeline has two assets. Budoprutug, an antibody against CD19, is being developed for primary membranous nephropathy, ITP and lupus. CLYM116 targets APRIL and is aimed at IgA nephropathy. Both sit in areas where companies are pursuing B-cell and plasma-cell biology, though the summary offers no comparison with rivals, market sizing or pricing assumptions.

The full deck was not available to CompePharma, and the summary contains no filing timelines, trial sizes, cash balance or spending figures. The runway guidance is a company projection, not a regulatory or clinical milestone.